122 related articles for article (PubMed ID: 38474332)
21. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
Tsao AN; Chuang YS; Lin YC; Su Y; Chao TC
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35417031
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
24. The Role of
Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
[TBL] [Abstract][Full Text] [Related]
25. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
26. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
27. Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
Howard D; James D; Garcia-Parra J; Pan-Castillo B; Worthington J; Williams N; Coombes Z; Rees SC; Lutchman-Singh K; Francis LW; Rees P; Margarit L; Conlan RS; Gonzalez D
Front Oncol; 2022; 12():1014280. PubMed ID: 36505806
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
[TBL] [Abstract][Full Text] [Related]
30. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors.
Funke K; Düster R; Wilson PD; Arévalo L; Geyer M; Schorle H
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406461
[TBL] [Abstract][Full Text] [Related]
32. CDK9 inhibition as an effective therapy for small cell lung cancer.
Valdez Capuccino L; Kleitke T; Szokol B; Svajda L; Martin F; Bonechi F; Krekó M; Azami S; Montinaro A; Wang Y; Nikolov V; Kaiser L; Bonasera D; Saggau J; Scholz T; Schmitt A; Beleggia F; Reinhardt HC; George J; Liccardi G; Walczak H; Tóvári J; Brägelmann J; Montero J; Sos ML; Őrfi L; Peltzer N
Cell Death Dis; 2024 May; 15(5):345. PubMed ID: 38769311
[TBL] [Abstract][Full Text] [Related]
33. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
[TBL] [Abstract][Full Text] [Related]
34. Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Xu L; Li L; Zhang J; Cai W; Zhao S; Liu S
Odontology; 2020 Apr; 108(2):300-311. PubMed ID: 31529315
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
[TBL] [Abstract][Full Text] [Related]
36. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
Alsayegh K; Matsuura K; Sekine H; Shimizu T
Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
[TBL] [Abstract][Full Text] [Related]
37. Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
Clin Cancer Res; 2024 Feb; 30(4):849-864. PubMed ID: 37703185
[TBL] [Abstract][Full Text] [Related]
38. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
39. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
[TBL] [Abstract][Full Text] [Related]
40. 5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.
Oing C; Verem I; Mansour WY; Bokemeyer C; Dyshlovoy S; Honecker F
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]